Latest Niacin Stories
WALTHAM, Mass., Jan. 25 /PRNewswire/ --Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of dyslipidemia, the rapid uptake of Roche/Japan Tobacco's first-in-class dalcetrapib and Merck's anacetrapib will drive $3.2 billion in sales of the cholesteryl ester transfer protein (CETP) inhibitors drug class in 2018 in the world's major pharmaceutical markets. Anacetrapib and dalcetrapib appear to be...
High-density lipoprotein (HDL), known as "good" cholesterol, isn't as protective for people with type 2 diabetes, according to research reported in Circulation: Journal of the American Heart Association.HDL carries cholesterol out of the arteries, and high levels are associated with a lower risk of heart disease. HDL also helps protect blood vessels by reducing the production of damaging chemicals, increasing the vessels' ability to expand, and repairing damage to the vessel...
Facing the increasing prevalence of type 2 diabetes worldwide in the past few decades, one may ask what is wrong with humans. Geneticists tell us that the human genome has not changed markedly in such a short time. Therefore, something must be happening in our environment or diet. As a matter of fact, dietary pattern is known to be closely linked to the development of type 2 diabetes. The increasing prevalence of type 2 diabetes following worldwide food fortification with niacin suggests that...
ABBOTT PARK, Ill., Dec. 10 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for two new dosage strengths of SIMCOR®, a cholesterol medication. SIMCOR is a fixed-dose combination of niacin extended-release and simvastatin. Abbott is seeking FDA approval for the following new dosage strengths of SIMCOR: 500/40 mg and 1000/40 mg (niacin extended-release/simvastatin). SIMCOR was approved...
BEVERLY HILLS, Calif., Nov. 20 /PRNewswire/ -- In the study presented today at the American Heart Association Scientific Sessions in Orlando, Florida today, The Effect of Extended-release Niacin or Ezetimibe Added to Chronic Statin Therapy On Carotid Intima Media Thickness (ARBITER 6-HALTS), study found that: Adding the cholesterol drug niacin to a statin improved HDL ("good") cholesterol levels and significantly reduced carotid arterial plaque buildup measured with ultrasound within 8...
Blood cholesterol levels improved, but arteries do not show itThe routine prescription of extended-release niacin, a B vitamin (1,500 milligrams daily), in combination with traditional cholesterol-lowering therapy offers no extra benefit in correcting arterial narrowing and diminishing plaque buildup in seniors who already have coronary artery disease, a new vascular imaging study from Johns Hopkins experts shows.In tests on 145 Baltimore-area men and women with existing atherosclerosis, all...
Statin therapy should still be used first to reach blood cholesterol levels before considering addition of niacinHeart experts at Johns Hopkins are calling premature the early halt of a study by researchers at Walter Reed Army Medical Center and Washington Hospital Center on the benefits of combining extended-release niacin, a B vitamin, with cholesterol-lowering statin medications to prevent blood vessel narrowing. Cardiovascular atherosclerosis, as it is also known, is believed responsible...
A new study has exposed weaknesses on the part of cholesterol-lowering drugs Zetia and Vytorin.In a recent study consisting of 208 patients, scientists looked at the primary ingredient of Zetia and Vytorin, called ezetimibe. They compared the ingredient to a B-vitamin known as niacin, which is available for much less than either prescription pill.Researchers found that patients that were given ezetimibe had lower levels of LDL cholesterol, while those who received niacin had less blockage in...
MAPLE GROVE, Minn., Nov. 16 /PRNewswire/ -- Results of the SLIM Study ("Slo-Niacin® and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia") were recently published in the Journal of Clinical Lipidology. The objective was to study the lipid and anti-inflammatory effects of Slo-Niacin® 1.5 g/day and Lipitor (atorvastatin calcium) 10 mg/day, given alone and then together in persons with features of combined hyperlipidemia, high triglycerides, low...
Study highlights: In patients with or at high-risk for coronary artery disease and LDL (bad cholesterol) treated with statins to < 100mg/dL but low HDL (good cholesterol), adding medication to raise HDL was compared with lowering LDL further. Patients were randomized to the addition of niacin (primarily to raise HDL), or ezetimibe (to further lower LDL cholesterol). Plaque buildup in the lining of the neck arteries was significantly reduced only in the niacin group. DUE TO AN EMBARGO...
